Versartis

Develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders.

Launch date

Dec 2008

Employees

Market cap

Enterprise valuation

Menlo Park California (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017
R&D budget	55.0m	68.0m	79.0m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	RA Capital Management Perceptive Advisors	N/A	-
Jun 2009	Index Ventures	$11.0m	Series A
Feb 2011	Advent Venture Partners Index Ventures New Leaf Venture Partners	$21.0m	Series B
Jan 2013	N/A	$25.0m	Series C
Jul 2013	N/A	$12.5m	Series C
Oct 2013	Advent Venture Partners Index Ventures Aisling Capital New Leaf Venture Partners Sofinnova Ventures	$20.0m	Series D
Feb 2014	Aisling Capital New Leaf Venture Partners Advent Life Sciences Sofinnova Ventures	$55.0m	Series E
Oct 2018*	Aravive Biologics	N/A	Merger
Total Funding		AUD223m

Tech stackLearn more about the technologies and tools that this company uses.

Financials